Show simple item record

dc.contributor.authorMarson, Justin
dc.contributor.authorLebwohl, Mark
dc.date.accessioned2023-03-03T19:41:26Z
dc.date.available2023-03-03T19:41:26Z
dc.date.issued2021-05-17
dc.identifier.citationMarson, J., & Lebwohl, M. (2021). Apremilast as an Off-Label Therapeutic Agent: A Comprehensive Review of Safety and Efficacy Data in the Literature for Combination Therapy and Inflammatory Dermatoses. SKIN The Journal of Cutaneous Medicine, 5(3), 203–227. DOI: 10.25251/skin.5.3.2en_US
dc.identifier.eissn2574-1624
dc.identifier.doi10.25251/skin.5.3.2
dc.identifier.urihttp://hdl.handle.net/20.500.12648/8483
dc.description.abstractObjective: To review the literature regarding the efficacy and safety of off-label use of apremilast in combination therapies for psoriasis and psoriatic arthritis and for other currently off-label inflammatory dermatoses. Methods: The Medline database was queried for all relevant articles published between 2014 and 2021 using exploded MeSH terms and keywords pertaining to the following themes: off-label, combination therapy, biologics, biologic therapy, methotrexate, and systemic psoriasis therapy. The Boolean term “AND” was used to find the intersection of these themes with the term “apremilast.” Results: 8 case series and 6 case reports investigated the use of apremilast in combination therapy for psoriasis and psoriatic arthritis. Addition of apremilast improved PASI scores by 31.8-77.4% among case series and 80-100% among case reports with adverse effects primarily consisting of gastrointestinal symptoms. 5 randomized-control trials (RCT), 9 open-label trials, 18 case series, and 30 case reports investigated the use of apremilast for off-label dermatoses. In RCTs, apremilast showed potential efficacy for atopic dermatitis and hidradenitis suppurativa. Open-label trials found apremilast efficacious for atopic dermatitis, allergic contact dermatitis, chronic pruritus, cutaneous sarcoidosis, discoid lupus erythematosus, hidradenitis suppurativa, lichen planus, prurigo nodularis, rosacea, and vitiligo. Limitations: Small sample size and short follow up duration for available randomized-control and open-label trials. Current data from case series/reports potentially limits generalizability of findings. Conclusion: Apremilast's safety profile makes it a potential efficacious, non-biologic systemic agent for monotherapy and combination therapy for a wide range of inflammatory dermatoses.en_US
dc.language.isoN/Aen_US
dc.publisherNational Society for Cutaneous Medicineen_US
dc.relation.urlhttps://jofskin.org/index.php/skin/article/view/1239en_US
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectApremilasten_US
dc.subjectInflammationen_US
dc.subjectPDE-4 Inhibitor,en_US
dc.subjectCombination Therapyen_US
dc.subjectOff-labelen_US
dc.titleApremilast as an Off-Label Therapeutic Agenten_US
dc.typeArticle/Reviewen_US
dc.source.journaltitleSKIN The Journal of Cutaneous Medicineen_US
dc.source.volume5
dc.source.issue3
dc.source.beginpage203
dc.source.endpage227
dc.description.versionVoRen_US
refterms.dateFOA2023-03-03T19:41:26Z
dc.description.institutionSUNY Downstateen_US
dc.description.departmentDermatologyen_US
dc.description.degreelevelN/Aen_US


Files in this item

Thumbnail
Name:
1239-Article Text-8372-1-10-20 ...
Size:
381.7Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 International
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivatives 4.0 International